RxDoctor Payments Data

Catherine Thomas, MD

Internal Medicine · Hattiesburg, MSNPI 1093796500

Payments from drug & device makers

$4,401in general payments, 2019–2025

Across 277 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$2K
  • Merck$340
  • Johnson & Johnson$258
  • Lilly USA, LLC$150
  • Theratechnologies Inc.$118
  • plus $163 from 3 others

What the payments were for

  • Food & beverage$4,37299%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company114$1,860
Gilead101$1,511
Merck17$340
Johnson & Johnson(2 entities)18$258
Lilly USA, LLC9$150
Theratechnologies Inc.7$118
AbbVie5$82
Novo Nordisk4$55
GSK2$26

How this compares

$4,401 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$325
Medicare patients
15
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala319$1,250,603
GenvoyaElviteg/Cob/Emtri/Tenof Alafen58$240,039
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf41$187,815
DovatoDolutegravir Sodium/Lamivudine66$187,560
TivicayDolutegravir Sodium75$162,406
JardianceEmpagliflozin183$144,644
JulucaDolutegravir/Rilpivirine44$143,199
PrezcobixDarunavir/Cobicistat60$140,520
DescovyEmtricitabine/Tenofov Alafenam46$100,793
OzempicSemaglutide68$80,006
IsentressRaltegravir Potassium27$52,936
LinzessLinaclotide46$36,398
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$35,248
PrezistaDarunavir17$32,664
JanuviaSitagliptin Phosphate36$31,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,511$1,591,435423 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca$1,860$493,166185 claims
Johnson & JohnsonPrezcobix$258$140,52060 claims
MerckIsentress, Januvia$340$84,70163 claims
Novo NordiskOzempic$55$80,00668 claims
AbbVieLinzess, Synthroid$82$37,34158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →